These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37334544)

  • 1. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
    Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
    J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
    Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
    Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
    Wu F; Chen L; Du Y
    Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
    Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
    Trials; 2014 Jan; 15():26. PubMed ID: 24433285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
    Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
    Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
    Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
    Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
    Yan F; Xue X; Lu J; Dalbeth N; Qi H; Yu Q; Wang C; Sun M; Cui L; Liu Z; He Y; Yuan X; Chen Y; Cheng X; Ma L; Li H; Ji A; Hu S; Ran Z; Terkeltaub R; Li C
    Arthritis Rheumatol; 2022 Dec; 74(12):2015-2023. PubMed ID: 35795968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
    Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
    Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
    Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
    Tiku A; Johnson DW; Badve SV
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):346-352. PubMed ID: 33767063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
    Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
    Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
    Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.